Metacrine is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. Their focus is on developing novel treatments for gastrointestinal (GI) and liver diseases. Metacrine originated at Salk Institute and has been investigating nuclear hormone receptors in metabolic diseases. They are leveraging their proprietary platform targeting farnesoid X receptors (FXR), nuclear receptor proteins involved in regulating metabolism, bile acid synthesis, and inflammation, and modulating liver and GI diseases. Their team has extensive chemistry and biology expertise resulting in a proprietary library of more than 2,500 compounds to modulate FXR. Metacrine is collaborating with Novo Nordisk on Type 2 Diabetes research and therapeutic development.

Metacrine

Founded: 2015
Location: San Diego, CA
Employee range: 11 - 50
Clinical stage: Clin0
Therapy area: IBD
Drug types: HEP, GI
Lead product: MET462
Funding: $85M IPO Sep 2020; $65M C Jun 2018; $22M B Dec 2017; $36M A Aug 2015

Drug notes:

About:

Jobs: